

<b>National Imaging Associates, Inc.*</b>	
<b>Clinical guidelines: NON-CANCEROUS CONDITIONS</b>	<b>Original Date: March 2015</b>
<b>Radiation Oncology</b>	<b>Last Revised Date: January 2022</b>
<b>Guideline Number: NIA_CG_135</b>	<b>Implementation Date: January 2023</b>

## INDICATIONS FOR RADIATION THERAPY

2D or 3D Conformal (3D CRT) is considered medically necessary for several non-malignant conditions, including but not limited to<sup>1</sup>:

- Prevention of keloid scars as an adjunctive therapy following excisional surgery
- Heterotopic ossification
- Pterygium in cases that cannot be medically managed
- Villonodular synovitis

Stereotactic Radiation Therapy (SRS, SBRT) is considered medically necessary when used in the treatment of non-malignant cranial lesions including the following<sup>2, 3</sup>:

- Arteriovenous malformation (AVM) of the brain or spine
- Trigeminal neuralgia that has not responded to other, more conservative, treatments
- Non-cancerous brain tumors such as acoustic neuroma, benign schwannomas, meningioma, hemangioma, pituitary adenoma, craniopharyngioma, neoplasm of the pineal gland, and chordomas

Also refer to NIA Stereotactic Radiation Therapy Guideline.

## TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW

Treatment for other non-malignant conditions utilizing proton beam, stereotactic radiation therapy (SBRT), or intensity modulated radiation therapy (IMRT) modalities should be referred to physician review.

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

1— Non-Cancerous Conditions

© 2019-2022 National Imaging Associates, Inc., All Rights Reserved

## BACKGROUND

Radiation therapy may have appropriate use in several non-malignant conditions. The treatment goal in patients with non-malignant conditions is to achieve relief of the indicated condition with radiation therapy with minimal risk of radiation exposure to sensitive structures.

## POLICY HISTORY

Date	Summary
January 2022	No significant changes
February 2021	No Changes
February 2020	References updated
February 2019	Added and updated references

## REFERENCES

1. McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, Taylor RE. Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. *Br J Radiol.* 2015;88(1056):20150405. doi:10.1259/bjr.20150405
2. American Society for Radiation Oncology. Model Policies: Stereotactic Body Radiation Therapy. American Society for Radiation Oncology (ASTRO). Updated June 2020. Accessed December 7, 2021. <https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/ASTROSBRTModelPolicy.pdf>
3. American Society for Radiation Oncology. Model Policies: Stereotactic Radiosurgery (SRS). American Society for Radiation Oncology (ASTRO). Updated 2014. Accessed December 9, 2021. [https://www.astro.org/uploadedFiles/MAIN\\_SITE/Daily\\_Practice/Reimbursement/Model\\_Policies/Content\\_Pieces/ASTROSRSModelPolicy.pdf](https://www.astro.org/uploadedFiles/MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/ASTROSRSModelPolicy.pdf)

## ADDITIONAL RESOURCES

1. Aggarwal A, Fersht N, Brada M. Radiotherapy for craniopharyngioma. *Pituitary.* Mar 2013;16(1):26-33. doi:10.1007/s11102-012-0429-1
2. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *Int J Radiat Oncol Biol Phys.* Mar 1 2010;76(3 Suppl):S3-9. doi:10.1016/j.ijrobp.2009.09.040
3. Casentini L, Fornezza U, Perini Z, Perissinotto E, Colombo F. Multisession stereotactic radiosurgery for large vestibular schwannomas. *J Neurosurg.* Apr 2015;122(4):818-24. doi:10.3171/2014.11.Jns131552
4. Combs SE, Engelhard C, Kopp C, et al. Long-term outcome after highly advanced single-dose or fractionated radiotherapy in patients with vestibular schwannomas - pooled results from 3 large German centers. *Radiother Oncol.* Mar 2015;114(3):378-83. doi:10.1016/j.radonc.2015.01.011
5. Ding D, Yen CP, Starke RM, Lee CC, Sheehan JP. Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy. *J Neurooncol.* Sep 2014;119(3):513-29. doi:10.1007/s11060-014-1501-7
6. Flickinger JC. A radiobiological analysis of multicenter data for postoperative keloid radiotherapy. *Int J Radiat Oncol Biol Phys.* Mar 15 2011;79(4):1164-70. doi:10.1016/j.ijrobp.2009.12.019
7. Gross CE, Frank RM, Hsu AR, Diaz A, Gitelis S. External beam radiation therapy for orthopaedic pathology. *J Am Acad Orthop Surg.* Apr 2015;23(4):243-52. doi:10.5435/jaaos-d-14-00022
8. Hasan S, Young M, Albert T, et al. The role of adjuvant radiotherapy after gross total resection of atypical meningiomas. *World Neurosurg.* May 2015;83(5):808-15. doi:10.1016/j.wneu.2014.12.037
9. Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *Int J Radiat Oncol Biol Phys.* Mar 1 2010;76(3 Suppl):S155-60. doi:10.1016/j.ijrobp.2009.08.074
10. Kondziolka D, Perez B, Flickinger JC, Habek M, Lunsford LD. Gamma knife radiosurgery for trigeminal neuralgia: results and expectations. *Arch Neurol.* Dec 1998;55(12):1524-9. doi:10.1001/archneur.55.12.1524

11. Luis AM. Radiotherapy for non-malignant diseases. *Reports of Practical Oncology & Radiotherapy*. 2013/06/01/ 2013;18:S14-S15. doi:<https://doi.org/10.1016/j.rpor.2013.04.004>
12. Maesawa S, Salame C, Flickinger JC, Pirris S, Kondziolka D, Lunsford LD. Clinical outcomes after stereotactic radiosurgery for idiopathic trigeminal neuralgia. *J Neurosurg*. Jan 2001;94(1):14-20. doi:10.3171/jns.2001.94.1.0014
13. Maniakas A, Saliba I. Microsurgery versus stereotactic radiation for small vestibular schwannomas: a meta-analysis of patients with more than 5 years' follow-up. *Otol Neurotol*. Dec 2012;33(9):1611-20. doi:10.1097/MAO.0b013e31826dbd02
14. Pashtan I, Oh KS, Loeffler JS. Radiation therapy in the management of pituitary adenomas. *Handb Clin Neurol*. 2014;124:317-24. doi:10.1016/b978-0-444-59602-4.00021-6
15. Popovic M, Agarwal A, Zhang L, et al. Radiotherapy for the prophylaxis of heterotopic ossification: a systematic review and meta-analysis of published data. *Radiother Oncol*. Oct 2014;113(1):10-7. doi:10.1016/j.radonc.2014.08.025
16. Portnow LH, Scott M, Morris CG, Mendenhall WM, Marcus RB, Jr., Indelicato DJ. Fractionated radiotherapy in the management of benign vascular tumors. *Am J Clin Oncol*. Dec 2012;35(6):557-61. doi:10.1097/COC.0b013e31821f847f
17. Seregard S, Pelayes DE, Singh AD. Radiation therapy: uveal tumors. *Dev Ophthalmol*. 2013;52:36-57. doi:10.1159/000351055
18. Seegenschmiedt MH, Micke O, Muecke R. Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines. *Br J Radiol*. Jul 2015;88(1051):20150080. doi:10.1259/bjr.20150080
19. Sonier M, Gete E, Herbert C, McKenzie M, Murphy J, Moiseenko V. Intensity-modulated stereotactic radiosurgery for arteriovenous malformations: guidance for treatment planning. *Radiat Oncol*. Mar 10 2014;9:73. doi:10.1186/1748-717x-9-73

**Reviewed / Approved by NIA Clinical Guideline Committee**

## GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.